- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00291200
Enhancing the Prospective Prediction of Psychosis
Обзор исследования
Статус
Условия
Подробное описание
Psychosis is a serious mental condition in which a person momentarily loses contact with reality. People in a state of psychosis may experience hallucinations or delusional beliefs that make day-to-day functioning difficult. During the early development of psychosis, people undergo an initial change in mood, thinking, or behavior that may include making mistakes about smells, sounds, or sights; becoming easily distracted; and developing suspicions of others. These basic symptoms can be early warning signs of a brain disorder, including anxiety disorder, depression, or psychotic disorder. Basic symptoms may be due to a number of factors, including a reaction to stress or drugs or just a part of normal adolescence. To identify psychosis early and accurately, more information is needed on the initial stages, biological markers, and progression of psychosis. This study will gather information on the natural history of the basic symptoms of psychosis to identify factors that may affect the improvement or persistence of the symptoms.
Participation in this study will last up to 5 years. The initial screening visit will be used to determine whether a participant is eligible for the group displaying basic symptoms or the control group. Initial screening will include giving a blood sample for routine lab tests, a physical exam, a drug test, and questions about medical history and symptoms. All participants will then partake in baseline evaluations, which involve assessments concerning concentration, problem solving, memory, social skills, and ability to identify smells. Participants will also respond to questions about symptoms, school and social functioning, stressful situations, and family history of illnesses. The participants who meet the criteria for basic symptoms will attend monthly 1-hour follow-up visits for the first year of the study. During these visits, participants will be asked about the status of their basic symptoms and use of medications. For the second year of the study, follow-up visits will occur every 2 months, and for the third, fourth, and fifth years of the study, visits will be every 3 months. Repeat baseline assessments will occur every 6 months, with each assessment visit lasting about 5 hours. All participants will undergo endpoint evaluations that follow the same format as most baseline assessments. Participants who develop a psychotic disorder during the study will attend an additional follow-up visit 6 months after the endpoint evaluation to confirm diagnosis. Participants who decide that they no longer wish to attend regular study visits may be asked to participate in follow-up telephone interviews about their basic symptoms every 6 months.
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
Ontario
-
Toronto, Ontario, Канада
- PRIME Clinic
-
-
-
-
Connecticut
-
New Haven, Connecticut, Соединенные Штаты, 06519
- Prevention through Risk Identification Management and Education (PRIME) Clinic
-
-
North Carolina
-
Chapel Hill, North Carolina, Соединенные Штаты, 27599
- PRIME Clinic
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Описание
Inclusion Criteria:
- Meets modified criteria of prodromal syndromes (COPS) for schizophrenia prodrome or help-seeking control
Exclusion Criteria:
- History of psychosis
- Antipsychotic treatment in the month prior to study entry
- More than 16 weeks of lifetime antipsychotic treatment
Учебный план
Как устроено исследование?
Детали дизайна
Когорты и вмешательства
Группа / когорта |
---|
1
Participants with basic symptoms of psychosis
|
2
Control participants
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
---|---|
Information on the natural history of basic symptoms of psychosis
Временное ограничение: Measured monthly during Year 1; every 2 months during Year 2; and every 3 months during Years 3, 4, and 5
|
Measured monthly during Year 1; every 2 months during Year 2; and every 3 months during Years 3, 4, and 5
|
Factors that may affect the improvement or persistence of basic symptoms of psychosis
Временное ограничение: Measured monthly during Year 1; every 2 months during Year 2; and every 3 months during Years 3, 4, and 5
|
Measured monthly during Year 1; every 2 months during Year 2; and every 3 months during Years 3, 4, and 5
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Scott W. Woods, MD, Yale School of Medicine
- Главный следователь: Jean Addington, PhD, University of Toronto
- Главный следователь: Diana O. Perkins, MD, MPH, University of North Carolina
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- MH61282
- 5U01MH066160 (Грант/контракт NIH США)
- DATR AD-P
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .